BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

Despite strong third-quarter revenues, BioNTech has softened its 2024 sales guidance in light of changes to Covid-19 vaccine ...

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...